EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer

Yannick Verhoeven, Delphine Quatannens, Sanne van der Heijden, Jari Claes, Julie de Beukelaar, Hilde Lambrechts, Christophe Hermans, Glenn Broeckx, Herwig Van Dijck, Ali Ramadhan, Karen Zwaenepoel, Hans Stoop und 9 weitere

Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014834

DOI: 10.1136/jitc-2026-014834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.05.2026. Verfasst von Yannick Verhoeven und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Oncological Research (CORE), University of Antwerp, Antwerp, Flanders, Belgium. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Receptors, Virus, Immunotherapy, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kom op tegen Kanker, Universitair Ziekenhuis Antwerpen, Multidisciplinary Oncology Center Antwerp.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite its viral etiology and immunogenic features, cervical cancer shows limited and often short-lived benefit from programmed cell death protein 1 blockade, currently the only approved immunotherapy for this disease. This limitation highlights the need for a deeper understanding of its immune microenvironment to uncover alternative or complementary immunotherapeutic targets that may improve outcomes.

Methods

We integrated spatial proteomic and bulk transcriptomic profiling of the cervical cancer immune landscape. Immune subset markers (CD8, CD4, CD68, FoxP3, NKp46) and clinically actionable immune checkpoint molecules (HLA-E, CD47, CD73, CD276, CD155, Gal-9, PD-L1, CD70, LAG-3) were assessed by immunohistochemistry in 65 resected tumors, spatially resolved across tumor stroma and tumor epithelium niches. Expression patterns and correlations with clinicopathological variables, immunotypes, and survival were systematically analyzed. Key findings were cross-validated in The Cancer Genome Atlas cohort, and tumor-killing assays were conducted to evaluate the therapeutic potential of identified checkpoint axes.

Results

Immune infiltration was predominantly localized to the tumor stroma, with CD8 + and CD4 + T cells as dominant subsets. Within the tumor epithelium, CD8 + T cells and CD68 + macrophages were most abundant. Among checkpoints, HLA-E and CD47 showed the highest and most widespread expression, whereas CD276 and CD155 were enriched in the tumor epithelium, and CD73 and CD70 in the tumor stroma. Squamous cell carcinoma showed a stronger immunologic profile than adenocarcinoma. Immunotype stratification revealed distinct expression profiles and prognostic patterns. Elevated niche-defined expression of CD8, CD4, CD4-FoxP3, and NKp46 associated with improved survival. CD155 emerged as the only checkpoint consistently linked with poor survival across niches and cohorts, and associated with chemotherapy resistance. Notably, CD155 was the most promising functional target and was highly and selectively enriched in the tumor epithelium across all immunotypes, including immune-desert tumors where other immune markers were scarce.

Conclusion

This study reveals a complex, niche-specific and immunotype-specific immunoregulatory architecture in cervical cancer that extends well beyond programmed death-ligand 1. CD155 stands out as a compelling and underused therapeutic target, supporting a paradigm shift in targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT) axis. Its functional impact and selective enrichment in the tumor epithelium positions CD155 as a promising therapeutic target for both checkpoint inhibition and epithelial-directed approaches in cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsReceptors, VirusImmunotherapyPrecision MedicineImmune Checkpoint InhibitorsHumansFemaleTumor MicroenvironmentBiomarkers, Tumor

Stichwörter der Autor:innen

Cervical CancerGene expression profiling - GEPHistologyImmunotherapyTumor microenvironment - TME

Substanzen

Receptors, Viruspoliovirus receptorImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Center for Oncological Research (CORE), University of Antwerp, Antwerp, Flanders, Belgium.
  • Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Flanders, Belgium.
  • Data Science Institute, I-Biostat, Hasselt University, Hasselt, Flanders, Belgium.
  • Department of Pathology, PA², General Hospital ZAS Middelheim, Antwerp, Flanders, Belgium.
  • Department of Pathology, University Hospital Antwerp, Edegem, Flanders, Belgium.
  • Department of Gynaecology, General Hospital ZAS Augustine, Wilrijk, Flanders, Belgium.

Förderung

  • Kom op tegen Kanker
  • Universitair Ziekenhuis Antwerpen
  • Multidisciplinary Oncology Center Antwerp
  • Fonds Wetenschappelijk Onderzoek
  • Flemish cancer society

Zitieren

APA

Verhoeven, Y., Quatannens, D., van der Heijden, S., Claes, J., de Beukelaar, J., Lambrechts, H., Hermans, C., Broeckx, G., Van Dijck, H., Ramadhan, A., Zwaenepoel, K., Stoop, H., Van Laere, S., Hauspy, J., Faes, C., van Kempen, L. C., Trinh, X. B., Lardon, F., Koljenovic, S., …, & De Waele, J. (2026). CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. Journal for ImmunoTherapy of Cancer, 14(5), e014834. https://doi.org/10.1136/jitc-2026-014834

Vancouver

Verhoeven Y, Quatannens D, van der Heijden S, Claes J, de Beukelaar J, Lambrechts H, et al. CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014834. doi:10.1136/jitc-2026-014834

BibTeX
@article{Verhoeven2026,
  author = {Verhoeven, Yannick and Quatannens, Delphine and van der Heijden, Sanne and Claes, Jari and de Beukelaar, Julie and Lambrechts, Hilde and Hermans, Christophe and Broeckx, Glenn and Van Dijck, Herwig and Ramadhan, Ali and Zwaenepoel, Karen and Stoop, Hans and Van Laere, Steven and Hauspy, Jan and Faes, Christel and van Kempen, Léon C and Trinh, Xuan Bich and Lardon, Filip and Koljenovic, Senada and van Dam, Peter André and De Waele, Jorrit},
  title = {CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {e014834},
  doi = {10.1136/jitc-2026-014834}
}
Kostenlos starten →